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BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY
TRIALS WITH COMBINED DRUGS
BY YING YUAN1 AND GUOSHENG YIN2
University of Texas and University of Hong Kong
We propose a new integrated phase I/II trial design to identify the most
efficacious dose combination that also satisfies certain safety requirements
for drug-combination trials. We first take a Bayesian copula-type model for
dose finding in phase I. After identifying a set of admissible doses, we imme-
diately move the entire set forward to phase II. We propose a novel adaptive
randomization scheme to favor assigning patients to more efficacious dose-
combination arms. Our adaptive randomization scheme takes into account
both the point estimate and variability of efficacy. By using a moving ref-
erence to compare the relative efficacy among treatment arms, our method
achieves a high resolution to distinguish different arms. We also consider
groupwise adaptive randomization when efficacy is late-onset. We conduct
extensive simulation studies to examine the operating characteristics of the
proposed design, and illustrate our method using a phase I/II melanoma clin-
ical trial.
1. Introduction. Phase I trials usually aim to find the maximum tolerated
dose (MTD) for an investigational drug, and phase II trials examine the efficacy
of the drug at the identified MTD. Traditionally, phase I and phase II trials are
conducted separately. There is a growing trend to integrate phase I and phase II
trials in order to expedite the process of drug development and reduce the associ-
ated cost [Gooley et al. (1994); Thall and Russell (1998); O’Quigley, Hughes and
Fenton (2001); Thall and Cook (2004); and Yin, Li and Ji (2006); among others].
The majority of these designs focus on single-agent clinical trials.
Treating patients with a combination of agents is becoming common in cancer
clinical trials. Advantages of such drug-combination treatments include the poten-
tial to induce a synergistic treatment effect, target tumor cells with differing drug
susceptibilities, or achieve a higher dose intensity with nonoverlapping toxicities.
Trial designs for drug-combination studies involve several distinct features that
are beyond the scope of methods for single-agent studies. In single-agent trials,
we typically assume that toxicity monotonically increases with respect to the dose.
However, in a drug-combination dose space, it is difficult to establish such order-
ing for dose combinations. Consequently, decision making for dose escalation or
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de-escalation is difficult in drug-combination trials due to the unknown toxicity
order. Another important feature that distinguishes drug-combination trials from
single-agent trials is the toxicity equivalent contour in the two-dimensional dose-
toxicity space. As a result, multiple dose combinations with similar toxicity may
be found in phase I drug-combination trials. For these reasons, single-agent phase
I/II designs cannot be directly applied to drug-combination trials.
In spite of a rich body of literature on phase I dose-finding designs for drug-
combination trials [Simon and Korn (1990); Korn and Simon (1993); Kramar,
Lebecq and Candalh (1999); Thall et al. (2003); Conaway, Dunbar and Peddada
(2004); Wang and Ivanova (2005); and Yin and Yuan (2009); among others], re-
search on phase I/II designs has been very limited. Recently, Huang et al. (2007)
proposed a parallel phase I/II clinical trial design for combination therapies, which,
however, only targets MTDs with a toxicity probability of 33% because the “3+3”
dose-finding design [Storer (1989)] is used in the phase I component.
Our research is motivated by a cancer clinical trial at M. D. Anderson Can-
cer Center for patients diagnosed with malignant melanoma. The experimental
agents to be combined are decitabine (a DNA methyltransferase inhibitor, which
has shown clinical activity in patients diagnosed with leukemia or myelodysplastic
syndrome) and a derivative of recombinant interferon which has been used to treat
cancer patients with advanced solid tumors. The primary objective of the trial is to
find the most effective, safe doses of both drugs when used in combination to treat
melanoma. For this trial, an integrated phase I/II design is more plausible to speed
up the drug discovery and reduce the total cost.
Toward this goal, we propose a new seamless phase I/II design to identify the
most efficacious dose combination that also satisfies certain safety requirements
for oncology drug-combination trials. In the phase I part of the trial, we employ
a systematic dose-finding approach by using copula-type regression to model the
toxicity of the drug combinations. Once phase I is finished, we take a set of ad-
missible doses to phase II, in which patients are adaptively randomized to multiple
treatment arms corresponding to those admissible doses. We propose a novel adap-
tive randomization (AR) procedure based on a moving reference to compare the
relative efficacy among the treatments in comparison. Our AR has a high resolution
to distinguish treatments with different levels of efficacy and thus can efficiently
allocate more patients to more efficacious arms. The proposed design allows us to
target any prespecified toxicity rate and fully utilize the available information to
make dose-assignment decisions.
The rest of the paper is organized as follows. In Section 2 we adopt a copula-
type probability model for toxicity and develop a new AR procedure for seamless
implementation of the phase I/II drug-combination trial design. In Section 3 we
apply our design to a melanoma clinical trial, and assess its operating character-
istics through extensive simulation studies. In Section 4 we extend the proposed
design to accommodate trials with late-onset efficacy using group sequential AR.
We conclude with a brief discussion in Section 5.
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2. Phase I/II drug-combination design.
2.1. Dose finding in phase I. For ease of exposition, consider a trial with a
combination of two agents, A and B; let ai be the prespecified toxicity probability
corresponding to Ai , the ith dose of drug A, with a1 < a2 < · · · < aI ; and let bj be
that of Bj , the j th dose of drug B, with b1 < b2 < · · · < bJ . Before the two drugs
are combined, each drug should have been thoroughly investigated when adminis-
tered alone. Given the relatively large dose-searching space and the limited sample
size in a drug-combination trial, it is critical to utilize the rich prior information
on ai and bj for dose finding. Typically, the maximum dose for each drug in the
combination is either the individual MTD determined in the single-agent trials or
a dose below the MTD. Therefore, the specification of ai and bj is quite accurate
because the upper bounds aI and bJ are known.
We employ the copula-type regression in Yin and Yuan (2009) to model the
joint toxicity probability πij at the dose combination (Ai,Bj ),
πij = 1 − {(1 − aαi )−γ + (1 − bβj )−γ − 1}−1/γ ,(2.1)
where α,β, γ > 0 are unknown model parameters. This model satisfies the natural
constraints for drug-combination trials. For example, if the toxicity probabilities
of both drugs are zero, the joint toxicity probability is zero; and if the toxicity
probability of either drug is one, the joint toxicity probability is one. Another at-
tractive feature of model (2.1) is that if only one drug is tested, it reduces to the
well-known continual reassessment method (CRM) for a single-agent dose-finding
design [O’Quigley, Pepe and Fisher (1990)].
Although model (2.1) takes a similar functional form as the Clayton copula
[Clayton (1978)], there are several fundamental differences [Yin and Yuan (2010)].
Copula models are widely used to model a bivariate distribution by expressing the
joint probability distribution through the marginal distributions linked with a de-
pendence parameter [for example, see Clayton (1978); Hougaard (1986); Genest
and Rivest (1993); and Nelsen (2006)]. In a drug-combination trial, we in fact only
observe a univariate dose-limiting toxicity (DLT) outcome for combined agents.
For a patient treated by combined agents (Ai,Bj ), a single binary variable X indi-
cates whether this patient has experienced DLT: that is, X = 1 with probability πij ,
and X = 0 with probability 1−πij . Therefore, model (2.1) is actually not a copula;
we simply borrow the structure of the Clayton copula to model the joint toxicity
probability when the two drugs are administered together. Moreover, model (2.1) is
indexed by three unknown parameters (α,β, γ ), in which γ is similar to the depen-
dence parameter in standard copula models and the two extra parameters α and β
render model (2.1) more flexibility to accommodate the complex two-dimensional
dose-toxicity surface for the purpose of dose finding. Analogous to the CRM, the
parameters α and β also account for the uncertainty of the prespecification of the
single-agent toxicity probabilities ai and bj , thereby enhancing the robustness of
our design to the misspecification of these prior toxicity probabilities.
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Suppose that at a certain stage of the trial, among nij patients treated at the
paired doses (Ai,Bj ), xij subjects have experienced DLT. The likelihood given
the observed data D is
L(α,β, γ |D) ∝
I∏
i=1
J∏
j=1
π
xij
ij (1 − πij )nij−xij .
In the Bayesian framework, the joint posterior distribution is given by
f (α,β, γ |D) ∝ L(α,β, γ |D)f (α)f (β)f (γ ),
where f (α), f (β) and f (γ ) denote vague gamma prior distributions with mean
one and large variances for α, β and γ , respectively. We derive the full conditional
distributions of these three parameters and obtain their posterior samples using the
adaptive rejection Metropolis sampling algorithm [Gilks, Best and Tan (1995)].
2.2. Adaptive randomization in phase II. Once the phase I dose finding is
complete, the trial seamlessly moves on to phase II for further efficacy evalua-
tion. Although the main purpose of phase I is to identify a set of admissible doses
satisfying the safety requirements, efficacy data are also collected. Based on the
efficacy data collected in both phase I and phase II, each new cohort of patients
enrolled in phase II are immediately randomized to a more efficacious treatment
arm with a higher probability. Similar to most of the phase I/II trial designs, pa-
tients in phase I and phase II need to be homogeneous by meeting certain eligibility
criteria, such that the efficacy data in phase I can be also used to guide adaptive
randomization in phase II.
For ease of exposition, we assume that K admissible doses have been found
in phase I and will be subsequently assessed for efficacy using K parallel treat-
ment arms in phase II. Let (p1, . . . , pK) denote the response rates corresponding
to the K admissible doses, and assume that among nk patients treated in arm k, yk
subjects have experienced efficacy. We model efficacy using the Bayesian hierar-
chical model to borrow information across multiple treatment arms:
yk|pk ∼ Bi(nk,pk),
pk ∼ Be(ζ, ξ),
(2.2)
ζ ∼ Ga(0.01,0.01),
ξ ∼ Ga(0.01,0.01),
where Bi(nk,pk) denotes a binomial distribution, and Be(ζ, ξ) denotes a beta dis-
tribution with a shape parameter ζ and a scale parameter ξ . We take vague gamma
prior distributions Ga(0.01,0.01) with mean one, for both ζ and ξ , to ensure that
the data dominate the posterior distribution. The posterior full conditional distribu-
tion of pk follows Be(ζ +yk, ξ +nk −yk), but those of ζ and ξ do not have closed
928 Y. YUAN AND G. YIN
forms. As the trial proceeds, we continuously update the posterior estimates of the
pk’s under model (2.2) based on the cumulating data.
The goal of response-AR is to assign patients to more efficacious treatment
arms with higher probabilities, such that more patients would benefit from better
treatments [Rosenberger and Lachin (2002)]. A common practice is to take the as-
signment probability proportional to the estimated response rate of each arm, for
example, using the posterior mean of pk (k = 1, . . . ,K). However, such an AR
scheme does not take into account the variability of the estimated response rates.
At the early stage of a trial, there is only a small amount of data observed, which
would lead to widely spread and largely overlapping posterior distributions of the
pk’s. In this situation, the estimated response rates of arms 1 and 2, say, pˆ1 = 0.5
and pˆ2 = 0.6, should not play a dominant role for patient assignment, because
more data are needed to confirm that arm 2 is truly superior to arm 1. Neverthe-
less, at a later stage, after more patients have been treated and a substantial amount
of data has become available, if we observe pˆ1 = 0.5 and pˆ2 = 0.6, we would
have more confidence in assigning more patients to arm 2, because its superiority
would then be much more strongly supported. Thus, in addition to the point esti-
mates of the pk’s, their variance estimates are also critical when determining the
randomization probabilities.
To account for the uncertainty associated with the point estimates, one can com-
pare the pk’s with a fixed target, say, p0, and take the assignment probability pro-
portional to the posterior probability pr(pk > p0|D). However, in the case where
two or more pk’s are much larger or much smaller than p0, their corresponding
posterior probabilities pr(pk > p0|D) are either very close to 1 or 0, and, there-
fore, this AR scheme would not be able to distinguish them.
Recognizing these limitations of the currently available AR methods, Huang et
al. (2007) arbitrarily took one study treatment as the reference, say, the first treat-
ment arm, and then randomized patients based on Rk = pr(pk > p1|D) for k > 1
while setting R1 = 0.5. For convenience, we refer to this method as fixed-reference
adaptive randomization (FAR), since each arm is compared with the same fixed ref-
erence to determine the randomization probabilities. By using one of the treatment
arms as the reference, FAR performs better than that using an arbitrarily chosen
target as the reference. Unfortunately, FAR cannot fully resolve the problem. For
example, in a three-arm trial if p1 is low but p2 and p3 are high, say, p1 = 0.1,
p2 = 0.4 and p3 = 0.6, FAR may have difficulty distinguishing arm 2 and arm 3,
because both R2 and R3 would be very close to 1. Even with a sufficient amount
of data to support the finding that arm 3 is the best treatment, the probabilities of
assigning a patient to arm 2 and arm 3 are still close. This reveals one limitation of
FAR that is due to the use of a fixed reference: the reference (arm 1) is adequate
to distinguish arm 1 from arms 2 and 3, but may not be helpful to compare arm 2
and arm 3. In addition, because R1 = 0.5, no matter how inefficacious arm 1 is,
it has an assignment probability of at least 1/5, if we use R1/(R1 + R2 + R3) as
the randomization probability to arm 1. Even worse, in the case of a two-arm trial
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with p1 = 0.1, and p2 = 0.6, arm 1 has a lower bound of the assignment probabil-
ity 1/3, which is true even if p1 = 0 and p2 = 1. This illustrates another limitation
of FAR that is due to the direct use of one of the arms as the reference for com-
parison. Moreover, the performance of FAR depends on the chosen reference, with
different reference arms leading to different randomization probabilities.
To fully address the issues with available AR schemes, we propose a new
Bayesian moving-reference adaptive randomization (MAR) method that accounts
for both the magnitude and uncertainty of the estimates of the pk’s. Unlike FAR,
the reference in MAR is adaptive and varies according to the set of treatment arms
under consideration. One important feature of MAR is that the set of treatments
in comparison is continuously reduced, because once an arm has been assigned
a randomization probability, it will be removed from the comparison set. By as-
signing randomization probabilities to treatment arms on a one-by-one basis, we
can achieve a high resolution to distinguish different treatments through such a
zoomed-in comparison. Based on the posterior samples of the pk’s, we diagram
the Bayesian MAR in Figure 1 and describe it as follows:
FIG. 1. Diagram of the proposed moving-reference adaptive randomization for a three-arm trial.
The top panels, from left to right, show that we first obtain posterior distributions of p1,p2,p3
and p¯; then calculate Rk = pr(pk > p¯|D) for k = 1,2,3; and assign the arm with the smallest value
of Rk (i.e., arm 1) a randomization probability π1. After spending π1, we remove arm 1 from the
comparison set and distribute the remaining randomization probability to the remaining arms (i.e,
arms 1 and 2) in a similar manner, as demonstrated in the bottom panels.
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1. Let A¯ and A denote the set of indices of the treatment arms that have and
have not been assigned randomization probabilities, respectively. We start with
A¯ = {·} an empty set, and A = {1,2, . . . ,K}.
2. Compute the mean response rate for the arms belonging to the set A, p¯ =∑
k∈Apk/
∑
k∈A 1, and use p¯ as the reference to determine Rk = pr(pk > p¯|D),
for k ∈ A. Identify the arm that has the smallest value of Rk , R = mink∈ARk .
3. Assign arm  a randomization probability of π,
π = R∑
k∈ARk
(
1 − ∑
k′∈A¯
πk′
)
,
and update A and A¯ by removing arm  from A into A¯. Note that π is a
fraction of the remaining probability 1 −∑k′∈A¯ πk′ because the assignment
probability of
∑
k′∈A¯ πk′ has already been “spent” in the previous steps.
4. Repeat steps 2 and 3 and keep spending the rest of the randomization probabil-
ity until all of the arms are assigned randomization probabilities, (π1, . . . , πK),
and then randomize the next cohort of patients to the kth arm with a probability
of πk .
The proposed MAR scheme has a desirable limiting property as given below.
THEOREM 2.1. In a randomized trial with K treatments, asymptotically, MAR
assigns patients to the most efficacious arm with a limiting probability of 1.
The proof is briefly outlined in the Appendix. In contrast, using FAR, the prob-
ability of allocating patients to the most efficacious arm may not converge to 1.
2.3. Phase I/II trial design. The proposed phase I/II drug-combination design
seamlessly integrates each trial component discussed previously. Let φT and φE
be the target toxicity upper limit and efficacy lower limit, and let n1 and n2 be
the maximum sample sizes for the phase I and phase II parts of the trial, respec-
tively. Let ce, cd , ca and cf be the fixed probability cutoffs for dose escalation,
de-escalation, dose admissibility and trial futility, the values of which are usually
calibrated through simulation studies such that the trial has desirable operating
characteristics. Our phase I/II design is displayed in Figure 2 and described as
follows:
1. In phase I, the first cohort of patients is treated at the lowest dose combination
(A1,B1).
2. During the course of the trial, at the current dose combination (Ai,Bj ):
(i) If pr(πij < φT |D) > ce, the doses move to an adjacent dose combina-
tion chosen from {(Ai+1,Bj ), (Ai+1,Bj−1), (Ai−1,Bj+1), (Ai,Bj+1)},
which has a toxicity probability higher than the current doses and clos-
est to φT . If the current dose combination is (AI ,BJ ), the doses stay at
the same levels.
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FIG. 2. Diagram of the proposed phase I/II trial design for drug-combination trials.
(ii) If pr(πij < φT |D) < cd, the doses move to an adjacent dose combina-
tion chosen from {(Ai−1,Bj ), (Ai−1,Bj+1), (Ai+1,Bj−1), (Ai,Bj−1)},
which has a toxicity probability lower than the current doses and closest
to φT . If the current dose combination is (A1,B1), the trial is terminated.
(iii) Otherwise, the next cohort of patients continues to be treated at the current
dose combination.
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3. Once the maximum sample size in phase I, n1, is reached, suppose that there
are K dose combinations with toxicity probabilities πij satisfying pr(πij <
φT |D) > ca , then they are selected as admissible doses and carried forward
to phase II in parallel.
4. In phase II, MAR is invoked to randomize patients among the K treatment
arms. Meanwhile, the toxicity and futility stopping rules apply to monitoring
each arm: if pr(πk < φT |D) < ca (over-toxic), or pr(pk > φE|D) < cf (futil-
ity), arm k is closed, k = 1, . . . ,K .
5. Once the maximum sample size in phase II, n2, is reached, the dose combina-
tion that has the highest posterior mean of efficacy is selected as the best dose.
In the proposed design, the response is assumed to be observable quickly so
that each incoming patient can be immediately randomized based on the efficacy
outcomes of previously treated patients. This assumption can be relaxed by using a
group sequential AR approach, when the response is delayed. The group sequential
AR updates the randomization probabilities after each group of patients’ outcomes
become available rather than after each individual outcome [Jennison and Turnbull
(2000)]. Our design is suitable for trials with a small number of dose combinations,
because all the dose combinations satisfying the safety threshold would be taken
into phase II. If a trial starts with a large number of dose combinations, many more
doses could make it into phase II, possibly some with toxicity much lower than
the upper bound. From a practical point of view, we could tighten the admissibility
criteria by choosing only those with posterior toxicity probabilities closest to φT .
The proposed phase I/II drug-combination trial design has been implemented
using C++. The executable file is available for free downloading at http://odin.
mdacc.tmc.edu/~yyuan/, and the source code is available upon request.
3. Application.
3.1. Motivating trial. We use a melanoma clinical trial to illustrate our
phase I/II drug-combination design. The trial examined three doses of decitabine
(drug A) and two doses of the derivative of recombinant interferon (drug B). The
toxicity upper limit was φT = 0.33, and the efficacy lower limit was φE = 0.2.
A maximum of 80 patients were to be recruited, with n1 = 20 for phase I, and
n2 = 60 for phase II. In the copula-type toxicity model, we specified the prior
toxicity probabilities of drug A as ai = (0.05,0.1,0.2), and those of drug B as
bj = (0.1,0.2). We elicited prior distributions Ga(0.5,0.5) for α and β , and
Ga(0.1,0.1) for γ . The dose-limiting toxicity was defined as any grade 3 or 4
nonhematologic toxicity, grade 4 thrombocytopenia, or grade 4 neutropenia lasting
more than two weeks or associated with infection. The clinical responses of inter-
est included partial and complete response. In this trial, it took up to two weeks
to assess both toxicity and efficacy, rendering the response-adaptive randomiza-
tion practically feasible. The accrual rate was two patients per month, and thus no
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FIG. 3. Adaptive randomization probabilities for the three admissible dose combinations in the
melanoma clinical trial.
accrual suspension was needed to wait for patients’ responses in order to assign
doses to new patients. It took approximately 10 months to conduct the phase I
part and two and a half years to complete the phase II part of the trial. We used
ce = 0.8 and cd = 0.45 to direct dose escalation and de-escalation, and ca = 0.45
to define the set of admissible doses in phase I. We applied the toxicity stopping
rule of pr(πk < φT |D) < ca and the futility stopping rule of pr(pk > φE|D) < cf
with cf = 0.1 in phase II. The decisions on dose assignment and adaptive random-
ization were made after observing the outcomes of every individual patient.
After 20 patients had been treated in the phase I part of the melanoma trial, three
dose combinations (A1,B1), (A1,B2) and (A2,B1) were identified as admissible
doses and carried forward to phase II for further evaluation of efficacy. During
phase II, the MAR procedure was used to allocate the remaining 60 patients to the
three dose combinations. Figure 3 displays the adaptively changing randomiza-
tion probabilities for the three treatment arms as the trial proceeded. In particular,
the randomization probability of (A2,B1) decreased first, and then increased; that
of (A1,B2) increased first and then decreased; and that of (A1,B1) kept decreas-
ing as the trial progressed. At the end of the trial, the dose combination (A2,B1)
was selected as the most desirable dose with the highest estimated efficacy rate
of 0.36.
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TABLE 1
Selection probability and number of patients treated at each dose combination using the proposed
phase I/II design, with the target dose combinations in boldface
Drug A Simulation results
True pr(toxicity) True pr(efficacy)Drug Selection Number of
Sc. B 1 2 3 1 2 3 percentage patients
1 2 0.1 0.15 0.45 0.2 0.4 0.6 1.0 25.2 18.3 8.8 17.0 15.3
1 0.05 0.15 0.2 0.1 0.3 0.5 0.0 10.7 42.8 8.5 11.3 18.0
2 2 0.1 0.2 0.5 0.2 0.4 0.55 4.0 44.5 2.8 11.3 21.2 8.1
1 0.05 0.15 0.4 0.1 0.3 0.5 0.3 24.0 19.2 9.7 15.8 11.4
3 2 0.1 0.15 0.2 0.2 0.3 0.5 1.7 7.0 67.1 8.3 10.9 31.3
1 0.05 0.1 0.15 0.1 0.2 0.4 0.0 1.9 19.8 8.2 7.9 11.9
4 2 0.1 0.4 0.6 0.3 0.5 0.6 16.3 25.4 0.2 16.1 15.1 3.7
1 0.05 0.2 0.5 0.2 0.4 0.55 3.9 46.2 3.1 14.2 22.3 5.7
5 2 0.1 0.2 0.25 0.3 0.5 0.2 7.6 52.8 0.3 11.1 19.9 13.4
1 0.05 0.15 0.2 0.2 0.4 0.4 0.8 20.5 15.4 10.2 12.5 11.2
6 2 0.05 0.05 0.05 0.2 0.3 0.5 0.3 5.2 77.8 7.5 9.6 37.9
1 0.05 0.05 0.05 0.1 0.2 0.4 0.0 0.3 16.0 7.7 6.7 10.4
7 2 0.1 0.2 0.5 0.2 0.4 0.5 4.2 41.8 9.3 10.6 20.3 10.7
1 0.05 0.15 0.2 0.1 0.3 0.4 0.5 10.7 29.8 9.5 12.1 15.0
8 2 0.5 0.55 0.6 0.5 0.5 0.5 0.0 0.0 0.0 0.4 0.3 0.1
1 0.5 0.55 0.6 0.5 0.5 0.5 0.1 0.0 0.0 7.3 0.4 0.1
9 2 0.4 0.72 0.9 0.44 0.58 0.71 0.5 0.0 0.0 3.6 1.6 0.3
1 0.23 0.4 0.59 0.36 0.49 0.62 23.9 3.7 0.0 20.9 6.0 0.8
10 2 0.24 0.56 0.83 0.4 0.6 0.78 10.8 2.5 0.0 11.6 6.0 1.2
1 0.13 0.25 0.42 0.32 0.5 0.68 19.0 41.6 3.3 22.1 19.9 4.0
11 2 0.15 0.25 0.4 0.3 0.41 0.54 17.1 35.4 17.2 13.3 16.5 12.8
1 0.11 0.15 0.2 0.15 0.22 0.31 1.6 7.3 11.3 10.8 10.3 9.8
12 2 0.15 0.19 0.23 0.17 0.33 0.55 1.6 10.1 54.1 7.7 11.3 25.6
1 0.12 0.15 0.19 0.1 0.22 0.39 0.3 4.2 17.9 9.0 8.2 10.5
3.2. Operating characteristics. We assessed the operating characteristics of
the proposed design via simulation studies. Under each of the 12 scenarios given
in Table 1, we simulated 1000 trials. In the Monte Carlo Markov chain (MCMC)
procedure, we recorded 2000 posterior samples for the model parameters after 100
burn-in iterations.
In each scenario, the target dose-combination is defined as the most efficacious
one belonging to the admissible set. We present the selection percentages and the
numbers of patients treated at all of the dose combinations. Scenarios 1–4 repre-
sent the most common cases in which both toxicity and efficacy increase with the
dose levels, while the target doses are located differently in the two-dimensional
space. The target dose is (A3,B1) in scenario 1, and (A2,B2) in scenario 2, which
not only had the highest selection probability, but was also the arm to which most
of the patients were randomized. In scenario 3 the target dose is the combination
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of the highest doses of drug A and drug B, for which the selection probability was
close to 70%, and more than 30 patients were treated at the most efficacious dose.
Scenario 4 also demonstrated a good performance of our design with a high selec-
tion probability of the target dose. In scenario 5 toxicity increases with the dose
but efficacy first increases then decreases, and in scenario 6 toxicity maintains at
a very low level, but efficacy gradually increases with the dose. Under these two
scenarios, both the selection probabilities and the numbers of patients allocated to
the target dose were plausible. Scenario 7 has two target doses due to the toxicity
and efficacy equivalence contours. In that scenario, both the target doses were se-
lected with much higher percentages and more patients were assigned to those two
doses than others. Scenario 8 demonstrated the safety of our design by success-
fully terminating the trial early when toxicity is excessive even at the lowest dose.
Scenarios 9–12 are constructed for a sensitivity analysis, which will be described
in Section 3.3.
To better understand the performance of the phase I part of the proposed design,
in Table 2 we display the percentage of each dose being selected into the admissi-
ble set, and the average number of admissible doses, K¯ , at the end of phase I. In
most of the cases, the selection percentages of the admissible doses were higher
than 90%, and the average number of admissible doses determined by the proposed
design was close to the true value. For example, in scenario 1, the true number of
admissible doses is 5, and our design, on average, selected 5.4 admissible doses
for further study in phase II.
As the number of admissible doses selected by phase I may vary from one trial
to another, the final trial results shown in Table 1 are jointly affected by both the
phase I and phase II parts of the design. To disassemble their intertwining ef-
fects, we conducted a simulation study with a focus on the adaptive randomization
TABLE 2
Selection percentage of each dose combination to the admissible set and the average size of the
admissible set, K¯ , in phase I. The true admissible doses are in boldface
% of admissible K¯ % of admissible K¯ % of admissible K¯
Scenario 1 Scenario 2 Scenario 3
97.8 95.2 67.9 5.4 97.9 92.2 38.2 4.9 99.6 99.0 91.8 5.9
98.1 98.0 91.9 98.8 98.2 72.6 99.7 99.7 98.3
Scenario 4 Scenario 5 Scenario 6
93.3 75.9 14.6 4.2 98.0 95.9 81.6 5.6 99.5 99.5 99.0 6.0
96.5 94.9 52.1 98.6 98.5 93.7 99.5 99.5 99.5
Scenario 7 Scenario 8 Scenario 9
97.9 94.6 55.6 5.3 2.0 0.9 0.3 0.1 24.9 10.5 0.4 1.2
98.8 98.5 86.1 3.1 2.4 0.9 42.7 36.6 11.6
Scenario 10 Scenario 11 Scenario 12
69.6 42.7 4.9 3.1 88.4 82.5 53.5 4.8 91.9 89.3 73.4 5.3
82.4 78.3 36.4 91.1 90.1 77.7 92.5 92.4 87.6
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TABLE 3
Number of patients randomized to each treatment arm using the fixed-reference adaptive
randomization (FAR) compared to the moving-reference adaptive randomization (MAR). The most
efficacious dose is in boldface
Response rate FAR MAR
Sc. Arm 1 Arm 2 Arm 3 Arm 1 Arm 2 Arm 3 Arm 1 Arm 2 Arm 3
1 0.1 0.2 0.3 27.7 31.8 40.6 12.5 29.0 58.5
2 0.2 0.1 0.3 40.5 17.2 42.4 27.3 13.0 59.7
3 0.3 0.1 0.2 61.1 13.7 25.2 58.4 13.1 28.5
4 0.1 0.3 0.6 23.3 33.8 42.9 5.5 13.3 81.3
5 0.3 0.6 0.1 34.4 54.6 11.0 13.9 80.5 5.5
6 0.6 0.3 0.1 82.2 12.5 5.3 81.8 12.8 5.3
7 0.01 0.4 0.6 21.0 38.7 40.3 3.7 20.6 75.7
8 0.01 0.01 0.5 25.8 25.1 49.1 5.3 5.3 89.4
only. In particular, we considered a phase II trial in which a total of 100 patients
would be randomized to three treatment arms. Table 3 shows the results based on
1000 simulated trials under eight different scenarios. Scenarios 1–3 simulate cases
in which the first arm has the lowest, intermediate and highest efficacy, respec-
tively. Scenarios 4–6 are constructed in a similar setting, but the efficacy differ-
ences among the three arms are much larger. Scenarios 7 and 8 consider cases in
which one or two arms are futile. In all of the scenarios, MAR allocated the ma-
jority of patients to the most efficacious arm in a more efficient way than FAR.
For scenarios 1, 3 and 8, in Figure 4 we show the randomization probabilities av-
eraged over 1000 simulations with respect to the cumulative number of patients
using MAR and FAR, respectively. As more data are collected, MAR has a sub-
stantially higher resolution to distinguish and separate treatment arms than FAR
in terms of efficacy. For example, in scenario 1 the curves are adequately sepa-
rated using MAR after 20 patients are randomized, but are still not well spread
even after enrolling 40 patients using FAR. Furthermore, considering scenarios 4,
5 and 6, we see that the number of patients assigned to the most efficacious arm
(with a response rate of 0.6) using FAR changed substantially from 42.9 to 82.2,
whereas that number stayed approximately the same as 81 when using MAR. This
phenomenon indicates the invariance of MAR and the sensitivity of FAR to the
reference arm.
3.3. Sensitivity analysis. In the first sensitivity analysis, we examined the ro-
bustness of the proposed design to model misspecifications. We generated true
toxicity and efficacy probabilities from the logistic regression model,
πij = exp(β0 + β1ZAi + β2ZBj + β3ZAiZBj )1 + exp(β0 + β1ZAi + β2ZBj + β3ZAiZBj ),(3.1)
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FIG. 4. Randomization probabilities of the proposed moving-reference adaptive randomization
(MAR) and the fixed-reference adaptive randomization (FAR) under scenarios 1, 3 and 8 listed in
Table 3.
but applied models (2.1) and (2.2) for estimation. We took the standardized doses
of drugs A and B in model (3.1) as ZAi = (0.05,0.1,0.2) and ZBj = (0.1,0.2).
These cases are listed as scenarios 9–12 in Table 1. When the models for toxicity
and efficacy were misspecified, our design still performed very well: the target
dose combination was selected with the highest probability and most of the patients
were allocated to those efficacious dose combinations.
In the second sensitivity analysis, we evaluated the impact of the prior specifica-
tions using two more diffusive prior distributions for α and β under scenarios 1–4.
The simulation results in Table 4 using the more diffusive priors are very close to
those for scenarios 1–4 in Table 1. Therefore, the proposed design does not appear
to be sensitive to the prior specification.
4. Late-onset efficacy. In practice, toxicity and efficacy outcomes need to be
ascertainable shortly after the initiation of the treatment in order to make a real-
time decision on the treatment assignment for each incoming patient. Often, tox-
icity can be observed quickly; whereas efficacy is late-onset, for example, tumor
shrinkage may take a relatively long time to assess. Such delayed efficacy out-
comes pose new challenges to the use of AR in randomized trials. We propose us-
ing the group sequential AR procedure, which adapts randomization probabilities
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TABLE 4
Sensitivity analysis of the proposed Bayesian phase I/II drug-combination design under different
prior specifications
Selection percentage Number of treated patients
Sc. α,β ∼ Ga(0.1,0.1) α,β ∼ Ga(0.05,0.05) α,β ∼ Ga(0.1,0.1) α,β ∼ Ga(0.05,0.05)
1 2.0 21.0 25.4 2.0 19.9 27.1 7.8 15.7 20.2 7.7 15.7 20.8
0.1 8.2 41.8 0 9.0 40.2 7.4 9.6 18.3 7.1 9.6 18.1
2 5.4 46.5 2.9 4.9 45.9 3.7 10.6 21.6 9.6 10.5 21.4 9.4
0.4 21.0 20.3 0.2 22.9 17.9 8.8 14.4 13.0 8.8 14.9 12.5
3 2.0 6.3 69.6 0.9 6.1 70.2 7.2 10.1 36.3 6.8 9.8 36.4
0.1 1.2 19.4 0 1.4 19.9 7.1 6.5 12.1 7.0 6.6 12.5
4 16.9 24.7 0.2 15.6 24.6 0.3 15.2 16.4 4.0 15.1 16.0 4.3
4.8 44.2 2.8 4.1 45.1 3.0 13.1 20.6 6.8 13.2 20.4 6.2
after a group of patients’ outcomes become available rather than after observing
each individual’s outcome [Karrison, Huo and Chappell (2003)]. More specifi-
cally, for the n2 patients to be randomized to K treatment arms in phase II, we up-
date the AR probabilities after observing every m patients’ outcomes, 1 ≤ m ≤ n2.
Choosing an appropriate m is critical for the practical performance of the group
sequential AR. With a larger value of m, the trial duration tends to be shortened
because we suspend the accrual less frequently, but it may downgrade the AR per-
formance. Using a smaller group size m, the group sequential AR procedure would
better facilitate assigning more patients to more efficacious treatment arms, but it
prolongs the trial duration. In addition to the group size, the performance of the
design also depends on the accrual rate, the length of the follow-up required for
efficacy assessment and the distribution of the time to efficacy.
To evaluate our design using the group sequential AR, we took efficacy to be
late-onset, requiring three months for a complete evaluation. We considered six
different group sizes: m = 1, 3, 6, 12, 20 and 30, corresponding to 1.7%, 5%, 10%,
20%, 33.3% and 50% of the total sample size, n2 = 60, in phase II. We investigated
two different accrual rates: two and eight patients per month, and simulated four
different patterns of the hazard for the time to efficacy: increasing, constant, de-
creasing and hump-shaped over time. The first three hazards were generated from
the Weibull distribution, and the hump-shaped hazard was generated from the log-
logistic distribution. Other design parameters, such as φT , ce, cd and ca , took the
same values as those in Section 3.1.
Table 5 shows the number of patients allocated to the target dose combination
and the duration of the trial under the first five scenarios listed in Table 1. In gen-
eral, when the size of the sequential group m increases, the number of patients al-
located to the target dose combination gradually decreases. This phenomenon was
minor when m increased from 1 to 6, but more notable when m became larger. For
example, in scenario 1 with an increasing hazard and an accrual rate of two pa-
tients per month, the numbers of patients allocated to the target dose combination
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TABLE 5
Number of patients allocated to the target dose combination and the trial duration (shown as
subscripts), with different group sizes m under scenarios 1–5
Hazard (accrual rate = 2/month) Hazard (accrual rate = 8/month)
m Increase Constant Decrease Hump Increase Constant Decrease Hump
Scenario 1
1 18.4157.8 18.1150.3 17.7139.5 17.8159.9 18.2149.4 17.5143.0 17.8131.5 17.4152.2
3 18.069.8 18.069.2 17.568.7 17.969.4 17.261.6 17.760.9 17.960.7 17.561.5
6 17.742.4 17.442.4 16.942.4 17.342.2 17.633.0 17.132.8 17.332.8 16.732.9
12 16.542.2 16.842.2 16.142.1 16.542.0 16.618.8 16.618.7 16.918.8 16.918.7
20 15.842.1 16.042.1 15.842.1 15.742.1 15.613.8 16.313.8 16.113.8 15.413.7
30 15.042.1 15.442.1 15.042.0 15.242.0 15.012.8 15.112.8 15.312.8 14.312.8
Scenario 2
1 21.0160.2 20.7153.7 22.5145.3 21.9162.3 21.3151.9 21.7146.9 22.0135.8 21.2154.5
3 20.869.5 21.669.4 21.968.6 21.569.2 21.361.3 21.261.2 21.560.8 20.961.1
6 20.742.3 21.142.1 21.742.2 20.942.1 20.732.8 21.632.7 21.832.6 20.932.6
12 20.542.0 20.842.0 21.242.1 20.941.9 20.518.6 20.818.6 21.018.7 20.618.7
20 20.242.0 19.142.1 20.242.0 20.842.1 20.013.7 19.313.7 20.113.8 19.613.7
30 19.142.2 19.642.1 19.641.9 19.742.1 18.612.8 19.612.8 18.512.8 19.312.8
Scenario 3
1 32.2161.2 32.0154.6 31.7144.7 31.1163.6 31.9153.8 32.0147.1 32.1136.6 32.3156.5
3 31.570.1 31.869.7 31.469.2 31.569.9 31.061.8 31.361.7 32.061.2 31.561.9
6 32.442.4 31.042.4 32.242.3 30.942.4 31.233.0 31.033.0 32.432.9 31.532.9
12 30.842.2 31.042.2 30.342.1 30.342.3 30.418.8 30.618.8 31.418.8 31.918.8
20 29.542.3 30.442.1 29.642.2 30.142.1 28.713.8 28.213.8 28.213.8 29.013.8
30 29.442.2 29.142.2 28.942.2 29.142.2 26.412.8 26.712.8 26.412.8 26.512.8
Scenario 4
1 23.0158.4 23.7151.5 22.8139.4 22.4159.5 23.5150.4 22.7143.8 22.3131.3 22.6151.9
3 22.769.1 22.368.9 22.668.7 22.469.1 22.361.0 22.860.9 21.959.8 21.061.2
6 21.842.4 21.742.2 22.542.3 21.342.3 22.232.6 21.932.8 22.432.9 21.532.7
12 21.242.1 21.341.9 20.742.1 21.041.8 20.418.6 22.018.7 21.918.7 21.218.7
20 20.242.1 20.342.1 19.842.0 20.142.0 20.013.7 20.113.7 19.913.7 20.313.8
30 19.342.2 19.342.1 18.642.1 19.442.2 19.512.8 19.212.7 20.212.8 18.912.8
Scenario 5
1 20.4159.7 21.3152.1 19.8141.1 20.3161.6 20.5152.4 20.5144.7 21.1133.4 20.9154.1
3 20.070.1 20.669.9 20.469.1 20.169.9 20.461.8 20.061.5 20.361.1 19.661.9
6 19.942.5 19.642.5 19.942.5 20.042.5 19.533.0 19.632.9 20.033.0 20.533.0
12 19.242.2 19.342.3 19.742.2 20.042.3 19.118.8 19.218.8 18.718.8 19.618.8
20 19.542.3 19.542.3 18.842.2 18.842.3 18.313.8 18.813.8 18.613.8 18.813.8
30 18.542.3 18.142.2 19.142.2 18.442.3 17.212.8 17.612.8 17.712.8 17.712.8
were 18.4, 17.7 and 15.0, when m = 1,6 and 30, respectively. The trial duration
was more sensitive to the value of m, and changed dramatically when the size of
the sequential group increased. When the accrual rate was two patients per month,
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we observed a substantial decrease in the trial duration when m increased from 1
to 6. For example, under scenario 2, the duration of the trial with m = 6 was ap-
proximately 1/4 of that with m = 1. However, when we further increased m from 6
to 30, the trial duration only changed slightly because in this circumstance the trial
duration was essentially dominated by the accrual rate, which is typically a key
factor affecting the trial duration. With a higher accrual rate of eight patients per
month, we observed additional reductions in the trial duration when m was larger
than 6, but as a trade-off, slightly fewer patients were allocated to the target dose
combination.
In practice, trial duration is an important factor to be considered when design-
ing clinical trials. We should choose an appropriate group size so as to achieve a
reasonable balance between AR and the trial duration. It is worth noting that the
group size is mainly used to determine when to update the randomization proba-
bilities, not when to randomize patients. Patients are randomized on a one-by-one
basis to the treatment arms no matter the size of the sequential group. In the ex-
treme case that the group size equals the total sample size, we essentially apply an
equal randomization scheme.
5. Concluding remarks. Drug-combination therapies are playing an increas-
ingly important role in oncology research. Due to the toxicity equivalence contour
in the two-dimensional dose-combination space, multiple dose combinations with
similar toxicity may be identified in a phase I trial. Thus, a phase II trial with AR
is natural and ethical to assign more patients to more efficacious doses. We have
adopted a copula-type model to select the admissible doses and proposed a novel
AR scheme when seamlessly connecting phase I and phase II trials. The attractive
feature of this phase I/II design is that once the admissible doses are identified,
AR immediately takes effect based on the efficacy data collected in the phase I
study. The proposed design efficiently uses all of the available data resources and
naturally bridges the phase I and phase II trials. In our design, AR is based only
on efficacy comparison among admissible doses. It can be easily modified to take
into account both toxicity and efficacy by using their odds ratio as a measure of the
trade-off or desirability to adaptively randomize patients and select the best dose
combination at the end of the trial [Yin, Li and Ji (2006)]. The proposed design
assumes that both toxicity and efficacy endpoints are binary. In some cases, these
endpoints can be ordinal or continuous, for example, it may be more direct to treat
the toxicity endpoint as an ordinal outcome to account for multiple toxicity grades.
To accommodate such an ordinal toxicity outcome, we can take the approach of
Yuan, Chappell and Bailey (2007) by first converting the toxicity grades to nu-
meric scores that reflect their impact on the dose allocation procedure, and then
incorporating those scores into the copula-type model using the quasi-binomial
likelihood. Another common scenario is that both toxicity and efficacy endpoints
take the form of time-to-event measurements. In this case, various survival models,
such as the proportional hazards model, are available to model the times to toxicity
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and efficacy. Along this direction, Yuan and Yin (2009) discussed jointly model-
ing toxicity and efficacy as time-to-event outcomes in single-agent trials; similar
approaches can be adopted here for phase I/II drug-combination trials.
APPENDIX: PROOF OF THEOREM 2.1
The proposed moving-reference adaptive randomization procedure is invariant
to the labeling of the treatment arms. Without loss of generality, we assume that
p1 < p2 < · · · < pK , and determine the randomization probability for arm 1. Start-
ing with A = {1,2, . . . ,K}, p¯ =∑Kk=1 pk/K . As the number of subjects goes to
infinity, it follows that the rank of Rk = pr(pk > p¯|D) is consistent with the order
of the pk’s, that is, R1 < R2 < · · · < RK . Therefore, for the first treatment arm
 = 1,
R = min
k∈ARk
= pr(p1 > p¯|D)
= pr{(p1 − p2) + (p1 − p3) + · · · + (p1 − pK) > 0|D}
≤ pr{(K − 1)(p1 − p2) > 0|D}
= pr(p1 > p2|D),
which converges to 0 asymptotically. Thus, π1 → 0, that is, the probability of as-
signing patients to the least efficacious arm goes to zero. Following similar argu-
ments, we can show that πk → 0 for k = 2, . . . ,K − 1. Therefore, the probability
of allocating patients to the most efficacious arm, πK = 1 −∑K−1k=1 πk , converges
to 1.
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